Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

IMPACT trial shows improvement in OS for metastatic CRPC

Dr. Neal Shore (GB) presented for the first time in Europe the updated results of the study "Sipuleucel-T Active Cellular Immunotherapy for Metastatic, Castration-Resistant Prostate Cancer: results from the IMPACT trial," during the second plenary session of the 25th Anniversary EAU Congress in Barcelona.

21 Apr 2010

BDSI Sciences to purchase $10M of securities in registered direct offering

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, announced that it has entered into a definitive securities purchase agreement with a group of select institutional investors to purchase US$10 million of its securities in a registered direct offering. No placement agent was utilized in connection with the offering.

21 Apr 2010

CytRx' bafetinib receives EMEA COMP positive opinion for treatment of CML

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that bafetinib (formerly known as INNO-406) has received official notification from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA) that a positive opinion was made regarding the application for orphan medicinal product for the treatment of chronic myeloid leukemia (CML).

20 Apr 2010

Aeterna Zentaris raises $13.7M through registered direct offering

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, announced today that it has completed its previously announced registered direct offering of US$15 million of units comprised of common shares and common share purchase warrants to certain institutional investors.

20 Apr 2010

Genentech to pay Seattle Genetics $9.5M for renewing licenses under existing ADC collaboration agreement

Seattle Genetics, Inc. today announced that Genentech, Inc., a wholly owned member of the Roche Group, will pay $9.5 million to renew exclusive licenses to specific targets and extend the research term under the parties' existing antibody-drug conjugate (ADC) collaboration agreement. Under the terms of the agreement, Genentech has rights to use Seattle Genetics' ADC technology with antibodies against targets selected by Genentech.

20 Apr 2010

MDx to better health care, cut costs and make personalized medicine a worldwide reality

The rapidly growing field of molecular diagnostics is addressing critical unmet needs in healthcare by enabling early disease detection and better disease segmentation, and by predicting relapse and response to therapy, according to a global industry review released today by Scientia Advisors.

20 Apr 2010

Investment report on Sequenom from MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring Sequenom Inc. The report includes financial, comparative and investment analysis, and industry information you need to know to make an educated investment decision.

20 Apr 2010

MicroStockProfit.com releases investment report on AEterna Zentaris

MicroStockProfit.com announces an investment report featuring AEterna Zentaris Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

20 Apr 2010

RANKL inhibition may prove effective in treatment of human malignancy, suggests study

Amgen today announced results of a preclinical study demonstrating a positive response to administration of RANK-Fc against mammary tumor formation in mouse models. OPG-Fc and RANK-Fc bind to and block the action of RANKL. These molecules have a comparable mechanism of action to denosumab. The study was presented today in a late-breaking abstract at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010 in Washington, D.C.

20 Apr 2010

Global guidelines for testing regimes for breast cancer patients

A cancer research specialist from the University of the West of England, Bristol is one of a panel of international experts who have had a report published in the Journal of Clinical Oncology today that gives new global guidelines for testing regimes for breast cancer patients. The guidelines relate to cancer patients with oestrogen and progesterone receptor positive breast tumours.

20 Apr 2010

Study underscores potential for VBL Therapeutics VB-111 as broad-spectrum cancer therapy

VBL Therapeutics today announced positive results from preclinical and Phase 1 studies evaluating the company's lead anti-cancer agent, VB-111 - a first-in-class, targeted biological agent shown to work via dual-action, anti-angiogenic and vascular disruptive mechanism of action - in metastatic cancer. Preclinical data evaluating VB-111 in a comprehensive set of in vivo studies employing the Lewis Lung metastasis mouse model showed the compound to be safe and specific, with a 90% reduction in tumor burden of lung metastases after only one injection.

20 Apr 2010

Global pharmaceutical market to reach $1.1 trillion in 2014: IMS Health

IMS Health reported today that the size of the global market for pharmaceuticals is expected to grow nearly $300 billion over the next five years, reaching $1.1 trillion in 2014. The 5 - 8 percent compound annual growth rate during this period reflects the impact of leading products losing patent protection in developed markets, as well as strong overall growth in the world's emerging countries.

20 Apr 2010

Hematological malignancies conference to provide update on blood-borne cancer

John Theurer Cancer Center at Hackensack University Medical Center will host a hematological malignancies conference for physicians and patients on Friday, April 23 and Saturday, April 24. The event, entitled "Current and Innovative Modalities in the Management of Hematological Malignancies", is part of John Theurer Cancer Center's commitment to provide both healthcare professionals as well as patients with an update on the newest advances in the field of blood-borne cancers.

20 Apr 2010

Dimerix Bioscience announces research agreement with Takeda Cambridge

Dimerix Bioscience Pty Ltd, a pre-clinical stage product company developing a pipeline of 'best in class' lead products with highly specific activity and with reduced risk of off-target effects, today announced that it has entered into a research agreement with Takeda Cambridge Limited, a UK based subsidiary of Takeda Pharmaceutical Company Limited, Japan's largest pharmaceutical company.

20 Apr 2010

Statin use may increase risk of developing benign colorectal tumors: APC trial

Statins did not protect patients against colorectal adenomas, which are benign precursors of colorectal cancer, according to results of a secondary analysis of the Adenoma Prevention with Celecoxib trial. In a population at high-risk for developing these lesions, results of this analysis suggested statin use may increase the risk of developing benign colorectal tumors.

20 Apr 2010

Study to assess and cut down on radiation exposure in cancer patients

Researchers are trying to assess and reduce the amount of radiation that Australian cancer patients are currently exposed to.

20 Apr 2010

Momenta Pharmaceuticals presents preclinical data of M402 at AACR 2010

Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex mixture drugs, today announced presentation of results from a preclinical study of its novel oncology drug candidate, M402, in a murine pancreatic cancer model.

20 Apr 2010

CombiMatrix announces operational restructuring plan

CombiMatrix Corporation announced today that it is implementing a restructuring plan to significantly reduce operating costs, increase the focus on the Company's diagnostic services business and transition senior management. After the restructuring, CombiMatrix will be focused on its diagnostics services business, including increasing utilization of its existing tests, expanding the test menu, increasing the number of customers and partners, and improving reimbursement for its testing services.

20 Apr 2010

FDA-approved metformin can prevent tobacco-carcinogen induced lung tumors: Study

Metformin, a mainstay of treatment for patients with type 2 diabetes, may soon play a role in lung cancer prevention if early laboratory research presented here at the AACR 101st Annual Meeting 2010 is confirmed in clinical trials.

20 Apr 2010

Cornerstone Pharmaceuticals obtains clearance for CPI-613 human clinical trial for hematologic malignancies

Cornerstone Pharmaceuticals, Inc., a private pharmaceutical company, with a singular focus on cancer metabolism, has announced today that U.S. regulatory clearance has been obtained for the initiation of a physician-sponsored, Phase I human clinical trial of Cornerstone's first-in-class anticancer agent, CPI-613.

20 Apr 2010